TY - JOUR
T1 - Monitoring eosinophils to guide therapy with Biologics in Asthma
T2 - does the compartment matter?
AU - Koenderman, Leo
AU - Hassani, Marwan
AU - Mukherjee, Manali
AU - Nair, Parameswaran
N1 - Funding Information:
Dr Nair was supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. Dr Mukherjee was supported by a Canadian Institutes of Health Research post‐doctoral fellowship. The data in the manuscript was supported by a grant from the Canadian Institute of Health Research.
Funding Information:
LK reports grants from GlaxoSmithKline and non‐financial support from Beckman Coulter. MH declares no conflicts of interests. MM reports grants from Methapharm Specialty Pharmaceuticals, Canadian Institute of Health Research, Canadian Asthma Allergy and Immunology Foundation and personal fees from AstraZeneca. PN reports grants and/or personal fees from AZ, Novartis, Teva, Sanofi, Roche, Novartis, Merck and Equillium.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Eosinophils, since their initial description by Thomas Wharton Jones in 1846, and staining characteristics by Paul Ehrlich in 1879, have been associated with asthma1 . They are produced in the bone marrow, from pluripotential stem cells, whichfirst differentiate, largely regulated by a transcription factor GATA-1, into a hybrid precursor for both basophils and eosinophils, and then into a separate eosinophil lineage. The eosinophilopoietins IL-3, GM-CSF and notably IL-5 regulatetheir further expansion and migration out of the bonemarrow into the circulation.Circulating eosinophils subsequently interactwith the endothelium by processes involving rolling, adhesion, and diapedesis. Depending on the targetorgan, eosinophils cross the endothelium into tissues by a regulated process involving the coordinatedinteraction between networks involving cytokines such as IL-13, the chemokine eotaxin-1, eosinophil adhesion molecules (α4β1, α4β7, αmβ2, αLβ2), and adhesion receptors on the endothelium (MAdCAM-1, VCAM-1, and ICAM-1). Under homeostatic conditions, eosinophils traffic into the thymus, mammary gland, uterus, and most prominently into the gastrointestinal tract.
AB - Eosinophils, since their initial description by Thomas Wharton Jones in 1846, and staining characteristics by Paul Ehrlich in 1879, have been associated with asthma1 . They are produced in the bone marrow, from pluripotential stem cells, whichfirst differentiate, largely regulated by a transcription factor GATA-1, into a hybrid precursor for both basophils and eosinophils, and then into a separate eosinophil lineage. The eosinophilopoietins IL-3, GM-CSF and notably IL-5 regulatetheir further expansion and migration out of the bonemarrow into the circulation.Circulating eosinophils subsequently interactwith the endothelium by processes involving rolling, adhesion, and diapedesis. Depending on the targetorgan, eosinophils cross the endothelium into tissues by a regulated process involving the coordinatedinteraction between networks involving cytokines such as IL-13, the chemokine eotaxin-1, eosinophil adhesion molecules (α4β1, α4β7, αmβ2, αLβ2), and adhesion receptors on the endothelium (MAdCAM-1, VCAM-1, and ICAM-1). Under homeostatic conditions, eosinophils traffic into the thymus, mammary gland, uterus, and most prominently into the gastrointestinal tract.
UR - http://www.scopus.com/inward/record.url?scp=85098522125&partnerID=8YFLogxK
U2 - 10.1111/all.14700
DO - 10.1111/all.14700
M3 - Article
C2 - 33301608
SN - 0105-4538
VL - 76
SP - 1294
EP - 1297
JO - Allergy
JF - Allergy
IS - 4
ER -